Key points are not available for this paper at this time.
The clinical candidate alpibectir augments the activity of, and overcomes resistance to, the anti-TB drug ethionamide in vitro and in vivo.
Building similarity graph...
Analyzing shared references across papers
Loading...
Michel Pieren
Ana Abáigar Gutiérrez-Solana
Rosa M. Antonijoan Arbos
Journal of Antimicrobial Chemotherapy
Medical University of Vienna
Universidad Autónoma de Madrid
GlaxoSmithKline (United States)
Building similarity graph...
Analyzing shared references across papers
Loading...
Pieren et al. (Fri,) studied this question.
www.synapsesocial.com/papers/68e72bb1b6db6435876a5e32 — DOI: https://doi.org/10.1093/jac/dkae107